iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
131 hedge funds and large institutions have $221M invested in iTeos Therapeutics in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 44 reducing their positions, and 24 closing their positions.
3.33% more ownership
Funds ownership: 93.46% → 96.8% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 44
4% less funds holding
Funds holding: 136 → 131 (-5)
16% less capital invested
Capital invested by funds: $262M → $221M (-$41.5M)
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
78% less call options, than puts
Call options by funds: $1.02M | Put options by funds: $4.67M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$18.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.4M |
| 3 |
6CM
683 Capital Management
New York
|
+$6.11M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$5.51M |
| 5 |
BlackRock
New York
|
+$5.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Boxer Capital Management
San Diego,
California
|
-$7.27M |
| 2 |
Citigroup
New York
|
-$6.13M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.67M |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$2.61M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.85M |
ITOS Hedge Fund Activity: Q1 2025 in Review
131 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q1 2025, worth a combined $221M — down 16% from $262M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ITOS and 19 opened new positions — a net loss of 5 holders — while 44 trimmed existing stakes and 43 added.
The largest buyer was Tang Capital Management, adding an estimated $18.1M. The largest seller was Boxer Capital Management, exiting entirely with an estimated $7.27M sold.
- 131 institutional investors held iTeos Therapeutics (ITOS) as of Q1 2025, down from 136 in Q4 2024.
- Funds reported $221M of iTeos Therapeutics stock for Q1 2025, down 16% quarter-over-quarter.
- 19 funds opened new iTeos Therapeutics positions in Q1 2025 and 24 closed out, a net change of -5 holders.
- The largest iTeos Therapeutics buyer in Q1 2025 was Tang Capital Management, an estimated $18.1M added.
- The largest iTeos Therapeutics seller in Q1 2025 was Boxer Capital Management, an estimated $7.27M sold.
Based on aggregated 13F filings for Q1 2025.